Efficacy of Imatinib Dose Escalation in Patients With Chronic Myeloid Leukemia in Chronic Phase

BACKGROUND: Imatinib mesylate given orally at a daily dose of 400 mg is the standard of care as initial therapy for patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP). Treatment guidelines propose dose escalation based on clinical assessments of disease response. METHODS: Respons...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer
Autores principales: Kantarjian, Hagop M., Larson, Richard A., Guilhot, Francois, O’Brien, Stephen G., Mone, Manisha, Rudoltz, Marc, Krahnke, Tillmann, Cortes, Jorge, Druker, Brian J.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2009
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4445370/
https://ncbi.nlm.nih.gov/pubmed/19117345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24066
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares